Abstract.
Solid tumors in humans are now believed to develop through a multistep process that activates oncogenes and inactivates tumor suppressor genes. Loss of heterozygosity at chromosomes 3p25, 3p22–24, 3p21.3, 3p21.2–21.3, 3p14.2, 3p14.3, and 3p12 has been reported in breast cancers. Retinoid acid receptor β2 (3p24), thyroid hormone receptor β1 (3p24.3), Ras association domain family 1A (3p21.3), and the fragile histidine triad gene (3p14.2) have been considered as tumor suppressor genes (TSGs) for breast cancers. Epigenetic change may play an important role for the inactivation of these TSGs. Screens for promoter hypermethylation may be able to identify other TSGs in chromosome 3p. Alternatively, use of an “epigenetic modifier” may enhance the response to another type of agent for breast cancer.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Additional information
Received: April 30, 2002 / Accepted: May 27, 2002
Rights and permissions
About this article
Cite this article
Yang, Q., Yoshimura, G., Mori, I. et al. Chromosome 3p and breast cancer. J Hum Genet 47, 453–459 (2002). https://doi.org/10.1007/s100380200064
Issue Date:
DOI: https://doi.org/10.1007/s100380200064
This article is cited by
-
TUSC2P suppresses the tumor function of esophageal squamous cell carcinoma by regulating TUSC2 expression and correlates with disease prognosis
BMC Cancer (2018)
-
The pseudogene TUSC2P promotes TUSC2 function by binding multiple microRNAs
Nature Communications (2014)
-
Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma
Tumor Biology (2014)
-
Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas
Journal of Translational Medicine (2012)
-
Topological analysis of gene expression arrays identifies high risk molecular subtypes in breast cancer
Applicable Algebra in Engineering, Communication and Computing (2012)